PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34093174-0	2021	Dexmedetomidine Protects Human Cardiomyocytes Against Ischemia-Reperfusion Injury Through alpha2-Adrenergic Receptor/AMPK-Dependent Autophagy.	Dexmedetomidine	0-15	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	117-121	
34093174-10	2021	Moreover, when pretreated with Dex, both the human ventricle and the iPSC-CMs expressed more AMP-activated protein kinase (AMPK) and phospho AMPK (pAMPK) during the I/R process.	Dexmedetomidine	31-34	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	93-121	
34093174-10	2021	Moreover, when pretreated with Dex, both the human ventricle and the iPSC-CMs expressed more AMP-activated protein kinase (AMPK) and phospho AMPK (pAMPK) during the I/R process.	Dexmedetomidine	31-34	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	123-127	
34093174-10	2021	Moreover, when pretreated with Dex, both the human ventricle and the iPSC-CMs expressed more AMP-activated protein kinase (AMPK) and phospho AMPK (pAMPK) during the I/R process.	Dexmedetomidine	31-34	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	141-145	
34093174-11	2021	After AMPK knockout or the use of an alpha2-adrenergic receptor antagonist-yohimbine, the protection of Dex and its enhancement of autophagy were inhibited.	Dexmedetomidine	104-107	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	6-10	
29393492-0	2018	Dexmedetomidine impairs P-glycoprotein-mediated efflux function in L02 cells via the adenosine 5"-monophosphate-activated protein kinase/nuclear factor-kappaB pathway.	Dexmedetomidine	0-15	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	85-136	
29393492-6	2018	Importantly, DEX-induced downregulation of P-gp was associated with adenosine 5"-monophosphate-activated protein kinase (AMPK) activation, as it was significantly attenuated by AMPK inhibition using dorsomorphin.	Dexmedetomidine	13-16	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	68-119	
29393492-6	2018	Importantly, DEX-induced downregulation of P-gp was associated with adenosine 5"-monophosphate-activated protein kinase (AMPK) activation, as it was significantly attenuated by AMPK inhibition using dorsomorphin.	Dexmedetomidine	13-16	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	121-125	
29393492-6	2018	Importantly, DEX-induced downregulation of P-gp was associated with adenosine 5"-monophosphate-activated protein kinase (AMPK) activation, as it was significantly attenuated by AMPK inhibition using dorsomorphin.	Dexmedetomidine	13-16	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	177-181	
29393492-7	2018	Furthermore, the results revealed that changes in the subcellular localisation of nuclear factor (NF)-kappaB following AMPK activation were involved in the P-gp regulation in response to DEX treatment.	Dexmedetomidine	187-190	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	119-123	
29393492-8	2018	Collectively, these results suggested that DEX impairs P-glycoprotein-mediated efflux function in L02 cells via the AMPK/NF-kappaB pathway, which provided direct evidence that the hepatic disposition of drugs may be affected by DEX through the downregulation of P-gp.	Dexmedetomidine	43-46	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	116-120